CommercialPrior AuthLow impact
Strensiq (asfotase alfa)
Blue Cross & Blue Shield of Mississippi·MS · Endocrinology, Pediatrics, Genetics·Medical Policy
Effective date
Jun 1, 2025
We identified it
Jun 20, 2026
Summary
BCBS Mississippi updated their prior authorization policy for Strensiq (asfotase alfa), a rare disease medication for hypophosphatasia, with revised medical necessity criteria and new renewal requirements effective June 1, 2025.
Action Required
By June 1, 2025: Update prior authorization protocols for Strensiq (asfotase alfa) to reflect new medical necessity criteria requiring ophthalmology examination and renal ultrasound at baseline, active disease documentation, and clinical manifestations prior to age 18. Update renewal criteria to require documented clinical improvement in respiratory status, growth, radiographic findings, or activity level. Train staff on revised criteria as this affects rare pediatric cases with hypophosphatasia.